Read More

EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics

Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and license agreement with Eterna Therapeutics Inc (NASDAQ:

ERNA